GENERIC DRUG;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
ROFECOXIB;
LACTONE;
SULFONE;
ARTICLE;
CARDIOVASCULAR DISEASE;
CONFLICT OF INTEREST;
DRUG FATALITY;
DRUG INDUSTRY;
DRUG MARKETING;
FUNDING;
GENE THERAPY;
HUMAN;
OFF LABEL DRUG USE;
ORNITHINE TRANSCARBAMYLASE DEFICIENCY;
PRACTICE GUIDELINE;
PRIMARY PREVENTION;
PRIORITY JOURNAL;
RESEARCH ETHICS;
SCIENTIFIC MISCONDUCT;
ETHICS;
FINANCIAL MANAGEMENT;
INTERPERSONAL COMMUNICATION;
MARKETING;
PHYSICIAN;
PUBLIC RELATIONS;
CONFLICT OF INTEREST;
DISCLOSURE;
DRUG INDUSTRY;
ETHICS, RESEARCH;
GENETIC THERAPY;
HUMANS;
INTERPROFESSIONAL RELATIONS;
LACTONES;
MARKETING;
PHYSICIANS;
RESEARCH SUPPORT AS TOPIC;
SULFONES;
Abramson JD, Redberg RF. Don't give more patients statins. New York Times. November 13, 2013 (http://www.nytimes.com/2013/11/14/opinion/dont-give-more-patients-statins.html).
Should people at low risk of cardiovascular disease take a statin?
[Erratum, BMJ 2014;348:g3329.]
Abramson JD, Rosenberg HG, Jewell N, Wright JM. Should people at low risk of cardiovascular disease take a statin? BMJ 2013;347:f6123. [Erratum, BMJ 2014;348:g3329.]
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:Suppl 2:S1-S45.
A national survey of physician-industry relationships
Campbell EG, Gruen RL, Mountford J, Miller LG, Cleary PD, Blumenthal D. A national survey of physician-industry relationships. N Engl J Med 2007;356:1742-50.
Stolberg SG. The biotech death of Jesse Gelsinger. New York Times Magazine. November 28, 1999 (http://www.nytimes.com/1999/11/28/magazine/the-biotech-death-of-jesse-gelsinger.html).
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
Glaxo agrees to pay $3 billion in fraud settlement
July 2
Thomas K, Schmidt MS. Glaxo agrees to pay $3 billion in fraud settlement. New York Times. July 2, 2012 (http://www.nytimes.com/2012/07/03/business/glaxosmithkline-agrees-to-pay-3-billion-in-fraud-settlement.html?pagewanted=all).
